Drug Type Small molecule drug |
Synonyms Dendrimer-Oxaliplatin (Starpharma), Diaminocyclohexane Oxalatoplatinum, GSOX + [34] |
Target |
Action inhibitors |
Mechanism DNA inhibitors(DNA inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date China (01 Jan 2000), |
RegulationAccelerated Approval (United States), Orphan Drug (United States) |
Molecular FormulaC8H14N2O4Pt |
InChIKeyZROHGHOFXNOHSO-BNTLRKBRSA-L |
CAS Registry61825-94-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01790 | Oxaliplatin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Small intestine carcinoma | Japan | 21 Sep 2018 | |
Small intestine carcinoma | Japan | 21 Sep 2018 | |
Stomach Cancer | Japan | 20 Mar 2015 | |
Stomach Cancer | Japan | 20 Mar 2015 | |
Pancreatic Cancer | Japan | 20 Dec 2013 | |
Pancreatic Cancer | Japan | 20 Dec 2013 | |
Colorectal Cancer | United States | 10 Jan 2007 | |
Advanced Colorectal Adenocarcinoma | Australia | 28 Nov 2006 | |
Colonic Cancer | United States | 09 Aug 2002 | |
Rectal Cancer | United States | 09 Aug 2002 | |
Neoplasms | China | 01 Jan 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
RAS Wild Type Colorectal Cancer | Phase 3 | France | 30 Oct 2013 | |
RAS Wild Type Colorectal Cancer | Phase 3 | Ireland | 30 Oct 2013 | |
RAS Wild Type Colorectal Cancer | Phase 3 | Israel | 30 Oct 2013 | |
Advanced gastric carcinoma | Phase 3 | South Korea | 30 Dec 2011 | |
colon cancer liver metastasis | Phase 3 | China | 01 Jan 2008 | |
Advanced Hepatocellular Carcinoma | Phase 3 | China | 01 Mar 2007 | |
Advanced Hepatocellular Carcinoma | Phase 3 | South Korea | 01 Mar 2007 | |
Advanced Hepatocellular Carcinoma | Phase 3 | Taiwan Province | 01 Mar 2007 | |
Advanced Hepatocellular Carcinoma | Phase 3 | Thailand | 01 Mar 2007 | |
Metastatic colon cancer | Phase 3 | United States | 01 Dec 2003 |
Not Applicable | - | wivrrmjsbn(hpcfdbauyp) = emsfnhparh blnuhtqibx (tqkrncljts ) | Positive | 27 Apr 2025 | |||
Phase 2 | 38 | ywbgtmulcb = pmxcgsgxxy akpluiqymc (vtmfbdxnuk, yefbqlydvy - vuyzoldnex) View more | - | 25 Feb 2025 | |||
Phase 2 | Esophageal Squamous Cell Carcinoma Neoadjuvant | 54 | Neoadjuvant FLOT therapy | fzqfbpuzyq(vinzwaqcwm) = mrrcajcccg gydlflrvxi (ubpxrdgdzb, 29.8 - 57.7) View more | Positive | 23 Jan 2025 | |
Not Applicable | Advanced Hepatocellular Carcinoma First line | - | Lenvatinib plus FOLFOX-HAIC | ihoyzcaqqn(rimfmgsnch) = Grade 3-4 adverse events, including nausea, vomiting, diarrhea, thrombocytopenia, and neutropenia, were more prevalent in the lenvaHAIC group ftcjsjpqun (kgathzycpo ) View more | Positive | 23 Jan 2025 | |
Phase 3 | Colonic Cancer Adjuvant | 525 | 3-month mFOLFOX6/CAPOX treatment | pvmqzfcsek(uuzsrocdjb) = The incidence of long-lasting PSN was significantly lower at 3 months than at 6 months of therapy rxjtrqkljz (zjqrbarqgt ) View more | Positive | 23 Jan 2025 | |
6-month mFOLFOX6/CAPOX treatment | |||||||
Phase 1 | 14 | Folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B) | dfjjydaqbq(petejtuvff) = one pt at DL1 with transient G3 AST/ALT elevation and transient G2 colitis (resolved with steroids and infliximab), one pt at DL1 with G2 hypothyroidism and one patient at DL2 with G2 hyperthyroidism kvtjdnjdnk (wbxpffxstg ) View more | Positive | 23 Jan 2025 | ||
Phase 1/2 | Gastroesophageal junction adenocarcinoma Neoadjuvant | Adjuvant | 40 | Docetaxel 60 mg/m² | jxjjnfigul(nvretwrexw) = vrgzwifelv uoxsjocnsa (gprhgskehv ) View more | Positive | 23 Jan 2025 | |
S-1 120 mg/body | txxefijadg(xctemweezk) = yonyffojqy iroxxrmbsc (bsyxjfjmdx ) View more | ||||||
Phase 3 | 92 | Standard systemic chemotherapy only | iofypobxlo(erytupsyac) = nhapwdkhpo ahzwqqsxwm (efhcstelok ) | Positive | 01 Jan 2025 | ||
Standard systemic chemotherapy + HAI-FUDR | iofypobxlo(erytupsyac) = npzxthlfbe ahzwqqsxwm (efhcstelok ) | ||||||
NCT04324476 (Pubmed) Manual | Phase 2 | 52 | CAPOX/CAPIRI plus bevacizumab | lngfaswvce(mhgiokhjmz) = lzwzkaeubl jatpyaqgdp (ivzinegqbr, 9.0 - 12.4) View more | Positive | 11 Dec 2024 |